Merck (MRK) announced that the U.S. FDA has approved Keytruda Qlex injection for subcutaneous administration in adults across most solid tumor indications for Keytruda. Berahyaluronidase alfa is a variant of human hyaluronidase developed and manufactured by Alteogen Inc. Keytruda Qlex must be administered by a health care provider. Merck expects to have Keytruda Qlex available in the U.S. in late September.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- FDA approves Merck’s Keytruda Qlex for solid tumor indications
- Merck receives positive EU CHMP opinion for Enflonsia
- Merck receives two positive EU CHMP opinions for Keytruda
- General Mills reports Q1 beat, Rithm to acquire Paramount Group: Morning Buzz
- Netflix upgraded, Five Below initiated: Wall Street’s top analyst calls